Tags

Type your tag names separated by a space and hit enter

Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
J Clin Hypertens (Greenwich). 2011 Oct; 13(10):731-8.JC

Abstract

The authors evaluated the blood pressure (BP)-lowering effects of combination valsartan/hydrochlorothiazide (HCTZ) vs. amlodipine/HCTZ in a 16-week, double-blind, randomized, forced-titration study and ambulatory BP monitoring (ABPM) substudy involving centrally obese hypertensive patients 40 years and older. Patients were started on valsartan/HCTZ 160/12.5 mg or HCTZ 12.5 mg monotherapy, force-titrated at week 4 to valsartan/HCTZ 320/25 mg and HCTZ 25 mg, respectively. The HCTZ group initiated amlodipine 5 mg at week 8 and 10 mg at week 12. A subset of patients had 24-hour ABPM at baseline and weeks 8 and 16. At week 16 in the intent-to-treat population (n=401), valsartan/HCTZ and amlodipine/HCTZ lowered office systolic BP (-30.6 vs. -28.3 mm Hg; P=.14). In the ABPM subgroup (n=111), valsartan/HCTZ was more effective than amlodipine/HCTZ in reducing 24-hour systolic BP (-20.6 vs. -14.5 mm Hg; P=.011). In obese hypertensive patients, valsartan/HCTZ reduced office BP similar to amlodipine/HCTZ but lowered 24-hour systolic BP more.

Authors+Show Affiliations

University of Miami-Nephrology, Miami, FL 33125-1624, USA. lraij@med.miami.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21974760

Citation

Raij, Leopoldo, et al. "Office and Ambulatory Blood Pressure-lowering Effects of Combination Valsartan/hydrochlorothiazide Vs. Hydrochlorothiazide-based Therapy in Obese, Hypertensive Patients." Journal of Clinical Hypertension (Greenwich, Conn.), vol. 13, no. 10, 2011, pp. 731-8.
Raij L, Egan BM, Zappe DH, et al. Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. J Clin Hypertens (Greenwich). 2011;13(10):731-8.
Raij, L., Egan, B. M., Zappe, D. H., Purkayastha, D., Samuel, R., & Sowers, J. R. (2011). Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. Journal of Clinical Hypertension (Greenwich, Conn.), 13(10), 731-8. https://doi.org/10.1111/j.1751-7176.2011.00499.x
Raij L, et al. Office and Ambulatory Blood Pressure-lowering Effects of Combination Valsartan/hydrochlorothiazide Vs. Hydrochlorothiazide-based Therapy in Obese, Hypertensive Patients. J Clin Hypertens (Greenwich). 2011;13(10):731-8. PubMed PMID: 21974760.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. AU - Raij,Leopoldo, AU - Egan,Brent M, AU - Zappe,Dion H, AU - Purkayastha,Das, AU - Samuel,Rita, AU - Sowers,James R, Y1 - 2011/07/14/ PY - 2011/10/7/entrez PY - 2011/10/7/pubmed PY - 2012/2/9/medline SP - 731 EP - 8 JF - Journal of clinical hypertension (Greenwich, Conn.) JO - J Clin Hypertens (Greenwich) VL - 13 IS - 10 N2 - The authors evaluated the blood pressure (BP)-lowering effects of combination valsartan/hydrochlorothiazide (HCTZ) vs. amlodipine/HCTZ in a 16-week, double-blind, randomized, forced-titration study and ambulatory BP monitoring (ABPM) substudy involving centrally obese hypertensive patients 40 years and older. Patients were started on valsartan/HCTZ 160/12.5 mg or HCTZ 12.5 mg monotherapy, force-titrated at week 4 to valsartan/HCTZ 320/25 mg and HCTZ 25 mg, respectively. The HCTZ group initiated amlodipine 5 mg at week 8 and 10 mg at week 12. A subset of patients had 24-hour ABPM at baseline and weeks 8 and 16. At week 16 in the intent-to-treat population (n=401), valsartan/HCTZ and amlodipine/HCTZ lowered office systolic BP (-30.6 vs. -28.3 mm Hg; P=.14). In the ABPM subgroup (n=111), valsartan/HCTZ was more effective than amlodipine/HCTZ in reducing 24-hour systolic BP (-20.6 vs. -14.5 mm Hg; P=.011). In obese hypertensive patients, valsartan/HCTZ reduced office BP similar to amlodipine/HCTZ but lowered 24-hour systolic BP more. SN - 1751-7176 UR - https://www.unboundmedicine.com/medline/citation/21974760/Office_and_ambulatory_blood_pressure_lowering_effects_of_combination_valsartan/hydrochlorothiazide_vs__hydrochlorothiazide_based_therapy_in_obese_hypertensive_patients_ L2 - https://doi.org/10.1111/j.1751-7176.2011.00499.x DB - PRIME DP - Unbound Medicine ER -